- Conditions
- Hepatitis D
- Interventions
- Lonafarnib, Ritonavir, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–18
of 18
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis Delta
- Interventions
- Peginterferon Lambda
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 8,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1992
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis D
- Interventions
- Lonafarnib, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug
- Drug · Other
- Lead sponsor
- Huahui Health
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Garden Grove, California
- Conditions
- Liver Disease, Hepatitis D
- Interventions
- Peg-interferon lambda, Lonafarnib, Ritonavir
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Viral Hepatitis
- Interventions
- Tobevibart, Elebsiran
- Drug
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Los Angeles, California • Redwood City, California + 8 more
- Conditions
- Chronic Hepatitis Delta
- Interventions
- GS-4321, GS-4321 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Anaheim, California • La Jolla, California • Louisville, Kentucky + 2 more
- Conditions
- Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
- Interventions
- Lamivudine
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD, NASH
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Garden Grove, California • Huntington Beach, California • Long Beach, California + 9 more
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Bulevirtide (BLV)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Edgewater, Florida • Miami, Florida • Miami Lakes, Florida + 4 more
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Davis, California • Sacramento, California • San Francisco, California + 5 more
- Conditions
- Hepatitis D, Chronic
- Interventions
- JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Redwood City, California • Boston, Massachusetts
- Conditions
- Chronic Hepatitis D Infection With Hepatitis B
- Interventions
- Not listed
- Lead sponsor
- Asian Pacific Liver Center at Coalition of Inclusive Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hepatitis Delta Virus
- Interventions
- Peginterferon Lambda-1a
- Drug
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Redwood City, California • San Francisco, California + 2 more
- Conditions
- Hepatitis D
- Interventions
- Peginterferon Alpha-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Hepatitis Delta
- Interventions
- Bulevirtide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York